Sotorasib interactions

Full monograph for Sotorasib Check it against another medicine

Medicines

349 documented

Severity

Mechanism

Medicines documented to interact with Sotorasib, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Aluminium Hydroxide + Magnesium Hydroxide	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.2 documented mechanisms	2 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide + Simethicone	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.2 documented mechanisms	2 sources — open the full entry
Aluminium Oxide + Magnesium Trisilicate	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Apalutamide	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Axitinib	Major	Metabolism	Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily…	2 sources — open the full entry
Brigatinib	Major	Metabolism	Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.	3 sources — open the full entry
Calcium acetate + Magnesium carbonate	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Calcium Carbonate	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Capmatinib Hydrochloride	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of capmatinib.	1 sources — open the full entry
Carbamazepine	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Cariprazine	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites.	4 sources — open the full entry
Daclatasvir	Major	Metabolism	Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…	2 sources — open the full entry
Daclatasvir + Sofosbuvir	Major	Metabolism	Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…	2 sources — open the full entry
Deflazacort	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active…	6 sources — open the full entry
Dexlansoprazole	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Elacestrant	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elacestrant, which is primarily…	1 sources — open the full entry
Enzalutamide	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Erdafitinib	Major	Metabolism	Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is…	1 sources — open the full entry
Esomeprazolebase MUPS preparation	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Esomeprazole + Amoxicillin + Clarithromycin	Major	Absorption · Metabolism	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.2 documented mechanisms	4 sources — open the full entry
Famotidine	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Fentanyl Citrate	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as…	10 sources — open the full entry
Finerenone	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily…	3 sources — open the full entry
Fosphenytoin Sodium	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Lansoprazole	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Lansoprazole + Amoxicillin + Clarithromycin	Major	Absorption · Metabolism	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.2 documented mechanisms	4 sources — open the full entry
Lefamulin Acetate	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin…	1 sources — open the full entry
Leflunomide	Major	Synergy	The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may…	3 sources — open the full entry
Lorlatinib	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lorlatinib, which may decrease its efficacy. In vitro studies have shown…	1 sources — open the full entry
Lurbinectedin	Major	Metabolism	Coadministration with a strong or moderate CYP450 3A4 inducer is predicted to decrease lurbinectedin systemic exposure, which may reduce its efficacy. No drug…	1 sources — open the full entry
Magaldrate	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Magaldrate + Simethicone	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Magnesium Hydroxide	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Magnesium Hydroxide + Liquid Paraffin	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Magnesium Oxide	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Mavacamten	Major	Metabolism	Coadministration with moderate to potent inducers of CYP450 2C19 and/or CYP450 3A4 may significantly decrease the plasma concentrations and therapeutic…	1 sources — open the full entry
Morphine Sulfate	Major	Absorption	Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including…	7 sources — open the full entry
Naproxen Sodium + Esomeprazole Magnesium	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Neratinib Maleate	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of neratinib, which is primarily…	2 sources — open the full entry
Olaparib	Major	Metabolism	Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily…	3 sources — open the full entry
Omeprazolebase MUPS tablet	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Pantoprazole Sodium	Major	Absorption	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.	2 sources — open the full entry
Phenobarbital	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Phenytoin Sodium	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Primidone	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sotorasib, which is partially metabolized by the…	2 sources — open the full entry
Rabeprazole + Amoxicillin + Clarithromycin	Major	Absorption · Metabolism	Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma.2 documented mechanisms	4 sources — open the full entry

Food & lifestyle

high-fat foods
Minor
Absorption
Food does not appear to have a clinically significant effect on the oral bioavailability of sotorasib. When a 960 mg dose of sotorasib was administered to study patients with a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively), sotorasib peak plasma concentration (Cmax) did not change while systemic exposure (AUC 0-24 hours) increased by 25% compared to administration under fasted conditions. Sotorasib can be administered with or without food at approximately the same time each day.
What to do: Sotorasib should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal. Patients should avoid consumption of high-fat foods during treatment with Sotorasib.
2 sources
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Lumakras (sotorasib)." Amgen USA (2021):

Medicines

Food & lifestyle

high-fat foods